Key Takeaways
- Sanara MedTech Inc. has received an Innovative Technology contract from Vizient Inc. for its BIASURGE Advanced Surgical Solution product
- The contract was awarded based on the recommendation of hospital experts who serve on one of Vizient’s client-led councils
- BIASURGE is a no-rinse irrigation solution designed to deliver more efficient surgical cleansing and provides broad-spectrum antimicrobial effectiveness
- The contract offers Vizient’s extensive network of healthcare facility customers with access to BIASURGE at contracted pricing and pre-negotiated terms
- Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market
Introduction to Sanara MedTech Inc. and the Contract Award
Sanara MedTech Inc., a medical technology company, has announced that its BIASURGE Advanced Surgical Solution product has received an Innovative Technology contract from Vizient Inc., the nation’s largest provider-driven healthcare performance improvement company. This contract is a significant milestone for Sanara MedTech Inc. as it signifies the potential of BIASURGE to bring improvement to the healthcare industry. The contract was awarded based on the recommendation of hospital experts who serve on one of Vizient’s client-led councils, which identifies technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety, or improve business operations of healthcare organizations.
Details of the BIASURGE Advanced Surgical Solution
BIASURGE is a no-rinse irrigation solution designed to deliver more efficient surgical cleansing. The solution contains an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms. It is indicated for mechanical cleansing and removal of debris, including microorganisms, from surgical wounds. BIASURGE’s proprietary formulation leverages synergistic technology, optimized for pH, viscosity, and osmolality, to ensure maximum performance while maintaining safety and effectiveness. The solution is suitable for use with irrigation systems and is specifically designed to address the demands of complex surgical scenarios. By enhancing surgical precision and visibility, BIASURGE supports infection-control strategies and contributes to improved surgical outcomes.
About Sanara MedTech Inc. and its Products
Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The company develops, markets, and distributes surgical products for use by physicians and clinicians in hospitals. Sanara’s products are primarily sold in the North American surgical tissue repair markets. The company’s portfolio includes a range of advanced biologic products, such as CellerateRX Surgical Activated Collagen Powder, BIASURGE Advanced Surgical Solution, FORTIFY TRG Tissue Repair Graft, FORTIFY FLOWABLE Extracellular Matrix, ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, and TEXAGEN Amniotic Membrane Allograft. Sanara MedTech Inc. believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements.
Forward-Looking Statements and Investor Relations
The statements in the press release that do not constitute historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as "aims," "anticipates," "believes," "contemplates," "continue," "could," "estimates," "expect," "forecast," "guidance," "intends," "may," "plans," "possible," "potential," "predicts," "preliminary," "projects," "seeks," "should," "targets," "will," or "would," or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the efficacy of BIASURGE, the potential sale of BIASURGE to Vizient clients upon award of the Innovative Technology contract, the company’s ability to improve its operating efficiency, the company’s business strategy and mission, the development of new products, the timing of commercialization of the company’s products, and the regulatory approval process. For investor relations, contact Jack Powell or Mike Piccinino, CFA, at ICR Healthcare, [email protected].
Conclusion and Future Prospects
In conclusion, Sanara MedTech Inc.’s receipt of the Innovative Technology contract from Vizient Inc. for its BIASURGE Advanced Surgical Solution product is a significant achievement for the company. The contract offers Vizient’s extensive network of healthcare facility customers with access to BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026. Sanara MedTech Inc. looks forward to engaging with Vizient’s clients to introduce BIASURGE and educate them on its potential to improve the treatment of surgical wounds. As a medical technology company, Sanara MedTech Inc. is committed to developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. With its portfolio of advanced biologic products and its focus on innovation, Sanara MedTech Inc. is well-positioned for future growth and success.